HKBU signed a Memorandum of Understanding (MOU) with CR Jiangzhong and the China Resources Research Institute of Science & Technology to reach an understanding on research into shenlingcao (參靈草) for treating post-COVID-19 syndrome.
The signing ceremony-cum-seminar was held on 7 December. The MOU was signed by Professor Terence Lau, Interim Chief Innovation Officer of HKBU; Mr Zhi Zhe, Vice President of the China Resources Research Institute of Science & Technology; and Mr Liu Wenjun, General Manager, R&D, China Resources Jiangzhong Pharmaceutical Group Co. Ltd. The ceremony was well attended by other representatives from the signing parties, including Mr Bai Xiaosong, CEO of China Resources Pharmaceutical Group Ltd.; Mr Yu Shunyan, Chairman of China Resources Double-Crane Pharmaceutical Co. Ltd.; and Professor Bian Zhaoxiang, Associate Vice-President (Chinese Medicine Development) of HKBU.
At the seminar, Professor Bian Zhaoxiang gave an overview of the School of Chinese Medicine and the University’s recent developments and research achievements in Chinese medicine. Mr Bai Xiaosong and Mr Yu Shunyan shared the research and development initiatives as well as the signature products of the China Resources Pharmaceutical Group. By leveraging the signing parties’ competitive advantages, more collaboration opportunities in Chinese medicine technological advancement and business incubation are expected.